Deborah M. Stephens

Deborah M. Stephens, DO

Languages spoken: English, Spanish

Academic Information

Departments Adjunct - Internal Medicine

Academic Office Information

Deborah.Stephens@hci.utah.edu

Board Certification

  • American Board of Internal Medicine (Sub: Hematology)
  • American Board of Internal Medicine (Sub: Medical Oncology)

Languages Spoken: English, Spanish



Deborah Stephens, DO joined the Division of Hematology and Hematologic Malignancies as an Assistant Professor in 2014. She completed her internal medicine residency at Cleveland Clinic and fellowship training at Ohio State University. Dr. Stephens’s clinic focuses on patients with chronic lymphocytic leukemia (CLL) and lymphoma. Her primary research interests include developing new targeted therapies for patients with CLL and lymphoma, studying resistance to current therapies, and developing supportive therapies for complications of CLL.. She is the Physician Leader of the Hematology Clinical Trials Division at Huntsman Cancer Institute and is the principal investigator on multiple clinical trials there. Her research has been widely published in influential journals such as the New England Journal of Medicine, Journal of Clinical Oncology, and Blood. She is a member of the editorial board for the Journal of Clinical Oncology. On a national level, she is an expert panelist for the National Comprehensive Cancer Network (NCCN) CLL Guidelines Panel, which establishes and published the most widely referenced guidelines for the evaluation and treatment of patients with CLL. Dr. Stephens is the Physician Leader of the SWOG CLL Working Group Committee, which is a group of CLL experts from academic centers around the country who plan and implement national clinical trials to improve the standard-of-care for CLL patients across the country. Dr. Stephens is also a member of the medical board for the CLL Society, which is the largest patient-led CLL group in the country. The sum of Dr. Stephens's experiences demonstrate her deep commitment to improve the care of patients with CLL and lymphoma.

Education History

Fellowship The Ohio State University Medical Center
 Chief Fellow
The Ohio State University
 Resident
Residency Cleveland Clinic
 Resident
Kansas City University of Medicine
 DO
Undergraduate The University of Iowa
 BS

Selected Publications

Journal Article

  1. Parsons MW, Rock C, Chipman JJ, Shah HR, Hu B, Stephens DM, Tao R, Tward JD, Gaffney DK (). Secondary malignancies in non-Hodgkin lymphoma survivors: 40 years of follow-up assessed by treatment modality. . (Epub ahead of print) J Natl Cancer Inst.
  2. Brown JR, Byrd JC, Ghia P, Sharman JP, Hillmen P, Stephens DM, Sun C, Jurczak W, Pagel JM, Ferrajoli A, Patel P, Tao L, Kuptsova-Clarkson N, Moslehi J, Furman RR (Pending). Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: Pooled analysis of 762 patients. 2021 Apr. Accepted for publication. (Epub ahead of print) Leukemia.
  3. Abbott J, Corean J, Snyder AM, Florell SR, Miles R, Stephens DM, Wada DA (Pending). Clinical and histologic spectrum of cutaneous hypersensitivity reactions in CLL/SLL patients with identification of T-cell papulosis of B-cell malignancy as a distinct subset. 2021 Mar. Submitted for review. (Epub ahead of print)
  4. Johnson PC, Woyach JA, Ulrich A, Marcotte V, Nipp RD, Lage DE, Nelson AM, Newcomb RA, Rice J, Lavoie MW, Ritchie CS, Bartlett N, Stephens DM, Ding W, Owen C, Stone R, Ruppert AS, Mandrekar SJ, Byrd JC, El-Jawahri A, Le-Rademacher J, Rosko A (2023). Geriatric assessment measures are predictive of outcomes in chronic lymphocytic leukemia. J Geriatr Oncol, 14(6), 101538.
  5. Siddiqi T, Maloney DG, Kenderian SS, Brander DM, Dorritie K, Soumerai J, Riedell PA, Shah NN, Nath R, Fakhri B, Stephens DM, Ma S, Feldman T, Solomon SR, Schuster SJ, Perna SK, Tuazon SA, Ou SS, Papp E, Peiser L, Chen Y, Wierda WG (2023). Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study. Lancet.
  6. Goyal G, Lau KW, Wang X, Davidoff AJ, Huntington SF, Jamy O, Calip G, Shah H, Stephens DM, Miksad R, Parikh RB, Takvorian S, Neparidze N, Seymour EK (2023). The COVID-19 Pandemic and In-Person Visit Rate Disruptions Among Patients With Hematologic Neoplasms in the US in 2020 to 2021. JAMA Netw Open, 6(6), e2316642.
  7. Wagner CB, Boucher K, Nedved A, Micallef IN, Desai S, Hatic H, Goyal G, Zacholski E, Fegley A, Sigmund AM, Bond DA, Samuels C, Kamdar MK, Ba Aqeel S, Torka P, MacDougall K, Borogovac A, Rajeeve S, Sundaram S, Fedak K, Modi D, Travers E, Ayyappan S, Chilakamarri N, Brem EA, Ermann DA, Fitzgerald LA, Hu B, Stephens DM, Shah H (2023). Effect of cumulative dose of brentuximab vedotin maintenance in relapsed/refractory classical Hodgkin lymphoma after autologous stem cell transplant: an analysis of realworld outcomes. Haematologica.
  8. Major A, Yu J, Shukla N, Che Y, Karrison TG, Treitman R, Kamdar M, Haverkos BM, Godfrey J, Babcook MA, Voorhees TJ, Carlson SG, Gaut D, Oliai C, Romancik JT, Winter AM, Hill BT, Bansal R, Villasboas JC, Nizamuddin IA, Karmali R, Fitzgerald LA, Stephens DM, Pophali PA, Trabolsi A, Schatz JH, Hu M, Bachanova V, Slade M, Singh N, Ahmed N, McGuirk JP, Bishop MR, Riedell PA, Kline J (2023). Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: Outcomes from 15 U.S. institutions. Blood Adv.
  9. Terpos E, Branagan AR, Garca-Sanz R, Trotman J, Greenberger LM, Stephens DM, Morel P, Kimby E, Frustaci AM, Hatjiharissi E, San-Miguel J, Dimopoulos MA, Treon SP, Leblond V (2023). Report of consensus panel 5 from the 11th international workshop on Waldenstrom's macroglobulinemia on COVID-19 prophylaxis and management. Semin Hematol, 60(2), 107-112.
  10. Shouse G, Kaempf A, Gordon MJ, Artz AS, Yashar D, Sigmund AM, Smilnak G, Bair SM, Mian A, Fitzgerald LA, Bajwa A, Jaglowski SM, Bailey N, Shadman M, Patel K, Stephens DM, Kamdar M, Hill BT, Gauthier J, Karmali R, Nastoupil LJ, Kittai AS, Danilov AV (2023). A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B cell lymphoma. Blood Adv.
  11. Fenlon JB, Hutten RJ, Johnson SB, Hu B, Shah H, Stephens DM, Maity A, Gaffney DK, Tao R (2022). Evaluating patterns of care for early-stage low-grade follicular lymphoma in the rituximab era. Leuk Lymphoma, 64(2), 356-363.
  12. Parsons MW, Rock C, Chipman JJ, Shah HR, Hu B, Stephens DM, Tao R, Tward JD, Gaffney DK (2022). Secondary malignancies in non-Hodgkin lymphoma survivors: 40 years of follow-up assessed by treatment modality. Cancer Med, 12(3), 2624-2636.
  13. Ujjani CS, Gooley TA, Spurgeon SE, Stephens DM, Lai C, Broome CM, OBrien SM, Zhu H, Laing KJ, Winter AM, Pongas G, Greninger AL, Koelle DM, Siddiqi T, Davids MS, Rogers KA, Danilov AV, Sperling AL, Tu B, Sorensen T, Launchbury KM, Burrow CJ, Quezada G, Hill JA, Shadman M, Thompson PA (2022). Diminished Humoral and Cellular Responses to SARS-CoV-2 Vaccines in Patients with Chronic Lymphocytic Leukemia. Blood Adv.
  14. Zurko JC, Nizamuddin I, Epperla N, David KA, Cohen JB, Moyo T, Ollila TA, Hess BT, Roy I, Ferdman R, Liu J, Chowdhury SM, Romancik JT, Bhansali RS, Harris EI, Sorrell M, Masel R, Kittai AS, Denlinger N, Sigmund AM, Fitzgerald LA, Galvez C, Ma S, Winter JN, Pro B, Gordon LI, Danilov AV, Stephens DM, Shah NN, Kenkre VP, Barta SK, Torka P, Shouse G, Karmali R (2022). Peri-CAR-T practice patterns and survival predictors for all CAR-T patients and post-CAR-T failure in aggressive B-NHL. Blood Adv.
  15. Stephens DM, Huang Y, Ruppert AS, Walker JS, Canfield D, Cempre CB, Fu Q, Baker S, Hu B, Shah H, Vadeboncoeur R, Rogers KA, Bhat S, Jaglowski SM, Lockman H, Lapalombella R, Byrd JC, Woyach JA (2021). Selinexor Combined with Ibrutinib Demonstrates Tolerability and Safety in Advanced B-Cell Malignancies: A Phase I Study. Clin Cancer Res, 28(15), 3242-3247.
  16. Rock CB, Chipman JJ, Parsons MW, Weil CR, Hutten RJ, Tao R, Tward JD, Shah HR, Hu B, Stephens DM, Gaffney DK (2022). Second Primary Malignancies in Diffuse Large B-cell Lymphoma Survivors with 40 Years of Follow Up: Influence of Chemotherapy and Radiation Therapy. Adv Radiat Oncol, 7(6), 101035.
  17. Stephens DM, Li H, Constine LS, Fitzgerald TJ, Leonard JP, Kahl BS, Song JY, LeBlanc ML, Smith SM, Persky DO, Friedberg JW (2022). Extranodal presentation in limited stage diffuse large B-cell lymphoma as a prognostic marker in three SWOG trials S0014, S0313 and S1001. Haematologica.
  18. Wierda WG, Brown J, Abramson JS, Awan F, Bilgrami SF, Bociek G, Brander D, Chanan-Khan AA, Coutre SE, Davis RS, Eradat H, Fletcher CD, Gaballa S, Ghobadi A, Hamid MS, Hernandez-Ilizaliturri F, Hill B, Kaesberg P, Kamdar M, Kaplan LD, Khan N, Kipps TJ, Ma S, Mato A, Mosse C, Schuster S, Siddiqi T, Stephens DM, Ujjani C, Wagner-Johnston N, Woyach JA, Ye JC, Dwyer MA, Sundar H (2022). NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022. J Natl Compr Canc Netw, 20(6), 622-634.
  19. Hu R, Wei W, Mian A, Gonter-Aubin K, Kabel C, Mato A, Stephens DM, Hanlon A, Khajavian S, Shadman M, Brander D, Madanat Y, Park JH, Tallman M, Pinilla-Ibarz J, Hill BT (2022). Treatment outcomes with purine nucleoside analog alone or with rituximab for hairy cell leukemia at first relapse. Eur J Haematol, 108(5), 379-382.
  20. Black GS, Huang X, Qiao Y, Tarapcsak S, Rogers KA, Misra S, Byrd JC, Marth GT, Stephens DM, Woyach JA (2022). Subclonal evolution of CLL driver mutations is associated with relapse in ibrutinib and acalabrutinib treated patients. Blood, 140, 401-405.
  21. Hamid MS, Rutherford SC, Jang H, Kim S, Patel K, Bartlett NL, Malecek MK, Watkins MP, Maddocks KJ, Bond DA, Feldman TA, Magarelli G, Advani RH, Spinner MA, Evens AM, Shah M, Ahmed S, Stephens DM, Allen P, Tees MT, Karmali R, Cheson BD, Yazdy MS, Strouse C, Bailey NA, Pagel JM, Ramchandren R (2021). Outcomes Among Classical Hodgkin Lymphoma Patients After an Interim PET Scan: A Real-World Experience. Clin Lymphoma Myeloma Leuk, 22, e435-e442.
  22. Stephens DM, Boucher K, Kander E, Parikh SA, Parry EM, Shadman M, Pagel JM, Cooperrider J, Rhodes J, Mato A, Winter A, Hill B, Gaballa S, Danilov A, Phillips T, Brander DM, Smith SM, Davids M, Rogers K, Glenn MJ, Byrd JC (2021). Hodgkin lymphoma arising in patients with chronic lymphocytic leukemia: outcomes from a large multi-center collaboration. Haematologica, 106(11), 2845-2852.
  23. Furman RR, Byrd JC, Owen RG, OBrien SM, Brown JR, Hillmen P, Stephens DM, Chernyukhin N, Lezhava T, Hamdy AM, Izumi R, Patel P, Baek M, Christian B, Dyer MJS, Streetly MJ, Sun C, Rule S, Wang M, Ghia P, Jurczak W, Pagel JM, Sharman JP (2021). Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies. Leukemia, 35(11), 3201-3211.
  24. Siddiqi T, Soumerai JD, Dorritie KA, Stephens DM, Riedell PA, Arnason JE, Kipps TJ, Gillenwater HH, Gong L, Yang L, Ogasawara K, Thorpe J, Wierda WG (2021). Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL. Blood, 139, 1794-1806.
  25. Stephens DM, Byrd JC (2020). Resistance to Bruton tyrosine kinase inhibitors: the Achilles heel of their success story in lymphoid malignancies. Blood, 138(13), 1099-1109.
  26. Brown JR, Byrd JC, Ghia P, Sharman JP, Hillmen P, Stephens DM, Sun C, Jurczak W, Pagel JM, Ferrajoli A, Patel P, Tao L, Kuptsova-Clarkson N, Moslehi J, Furman RR (2021). Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients. Haematologica, 107, 1335-1346.
  27. Orellana-Noia VM, Reed D, McCook AA, Sen JM, Barlow CM, Malecek MK, Watkins MP, Kahl BS, Spinner MA, Advani R, Voorhees TJ, Snow A, Grover NS, Ayers AA, Romancik J, Liu Y, Huntington SF, Chavez JC, Saeed H, Lazaryan A, Raghunathan V, Spurgeon SE, Ollila TA, Del Prete C, Olszewski A, Ayers EC, Landsburg DJ, Echalier B, Lee J, Kamdar M, Caimi PF, Fu T, Liu J, David KA, Alharthy H, Law JY, Karmali R, Shah HR, Stephens DM, Major A, Rojek AE, Smith SM, Yellala A, Kallam A, Nakhoda S, Khan N, Sohail MA, Hill BT, Barrett-Campbell O, Lansigan F, Switchenko JM, Cohen JB, Portell CA (2021). Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions. Blood, 139, 413-423.
  28. Gordon MJ, Kaempf A, Sitlinger A, Shouse G, Mei M, Brander DM, Salous T, Hill BT, Alqahtani H, Choi M, Churnetski MC, Cohen JB, Stephens DM, Siddiqi T, Rivera X, Persky D, Wisniewski P, Patel K, Shadman M, Park B, Danilov AV (2021). The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity Model. Clin Cancer Res, 27(17), 4814-4824.
  29. Byrd JC, Woyach JA, Furman RR, Martin P, OBrien S, Brown JR, Stephens DM, Barrientos JC, Devereux S, Hillmen P, Pagel JM, Hamdy A, Izumi R, Patel P, Wang MH, Jain N, Wierda WG (2020). Acalabrutinib in treatment-naive chronic lymphocytic leukemia. Blood, 137(24), 3327-3338.
  30. Gordon MJ, Kaempf A, Sitlinger A, Shouse G, Mei M, Brander DM, Salous T, Hill BT, Alqahtani H, Choi M, Churnetski MC, Cohen JB, Stephens DM, Siddiqi T, Rivera X, Persky D, Wisniewski P, Patel K, Shadman M, Park B, Danilov AV (2021). The chronic lymphocytic leukemia comorbidity index (CLL-CI): a three-factor comorbidity model. Clin Cancer Res.
  31. Shah H, Stephens D, Seymour J, Maddocks K (2021). Incorporating Novel Targeted and Immunotherapeutic Agents in Treatment of B-Cell Lymphomas. Am Soc Clin Oncol Educ Book, 41, 1-18.
  32. Kittai AS, Huang Y, Gordon M, Denlinger N, Mian A, Fitzgerald L, Bishop J, Nagle S, Stephens DM, Jaglowski S, Hill B, Danilov AV (2020). Comorbidities Predict Inferior Survival in Patients Receiving Chimeric Antigen Receptor T Cell Therapy for Diffuse Large B Cell Lymphoma: A Multicenter Analysis. Transplant Cell Ther, 27(1), 46-52.
  33. Feusier JE, Madsen MJ, Avery BJ, Williams JA, Stephens DM, Hu B, Osman AEG, Glenn MJ, Camp NJ (2021). Shared genomic segment analysis in a large high-risk chronic lymphocytic leukemia pedigree implicates CXCR4 in inherited risk. 5, 189-199.
  34. Persky DO, Li H, Stephens DM, Park SI, Bartlett NL, Swinnen LJ, Barr PM, Winegarden JD 3rd, Constine LS, Fitzgerald TJ, Leonard JP, Kahl BS, LeBlanc ML, Song JY, Fisher RI, Rimsza LM, Smith SM, Miller TP, Friedberg JW (2020). Positron Emission Tomography-Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001. J Clin Oncol, 38(26), 3003-3011.
  35. Koffman B, Mato A, Byrd J, Danilov A, Hedrick B, Ujjani C, Roeker L, Stephens DM, Davids M, Pagel JM, Shadman M (2020). A survey of CLL experts opinion on management of patients during the COVID-19 pandemic. J Clin Oncol, E199-E203..
  36. Byrd JC, Wierda WG, Schuh A, Devereux S, Chaves JM, Brown JR, Hillmen P, Martin P, Awan FT, Stephens DM, Ghia P, Barrientos J, Pagel JM, Woyach JA, Burke K, Covey T, Gulrajani M, Hamdy A, Izumi R, Frigault MM, Patel P, Rothbaum W, Wang MH, OBrien S, Furman RR (2018). Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results. Blood, 135(15), 1204-1213.
  37. Wierda WG, Byrd JC, Abramson JS, Bilgrami SF, Bociek G, Brander D, Brown J, Chanan-Khan AA, Chavez JC, Coutre SE, Davis RS, Fletcher CD, Hill B, Kahl BS, Kamdar M, Kaplan LD, Khan N, Kipps TJ, Lim MS, Ma S, Malek S, Mato A, Mosse C, Shadman M, Siddiqi T, Stephens D, Sundaram S, Wagner N, Dwyer MA, Sundar H (2020). Chronic lymphocytic leukemia/small lymphocytic lymphoma, Version 4.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw, 18(2), 185-217.
  38. Wierda WG, Byrd JC, Abramson JS, Bilgrami SF, Bociek G, Brander D, Brown J, Chanan-Khan AA, Chavez JC, Coutre SE, Davis RS, Fletcher CD, Hill B, Kahl BS, Kamdar M, Kaplan LD, Khan N, Kipps TJ, Lim MS, Ma S, Malek S, Mato A, Mosse C, Shadman M, Siddiqi T, Stephens D, Sundaram S, Wagner N, Dwyer M, Sundar H (2020). Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 18(2), 185-217.
  39. Gordon MJ, Sitlinger A, Salous T, Alqahtani H, Churnetski M, Rivera X, Wisniewski P, Cohen J, Patel K, Shadman M, Choi M, Hill B, Stephens DM, Persky D, Brander D, Danilov AD (2020). A simplified prognostic index for chronic lymphocytic leukemia treated with ibrutinib: results from a multicenter retrospective cohort study. Leuk Res Treatment, 89.
  40. Stephens DM (2019). Venetoclax and obinutuzumab for frontline treatment of chronic lymphocytic leukemia. Blood, 134(20), 1691-1696.
  41. Stephens DM, Li H, Schder H, Straus DJ, Moskowitz CH, LeBlanc M, Rimsza LM, Bartlett NL, Evens AM, LaCasce AS, Barr PM, Knopp MV, Hsi ED, Leonard JP, Kahl BS, Smith SM, Friedberg JW (2019). Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma. Blood, 134(15), 1238-1246.
  42. Geer M, Roberts E, Shango M, Till BG, Smith SD, Abbas H, Hill BT, Kaplan J, Barr PM, Caimi P, Stephens DM, Lin E, Herrera AF, Rosenbaum E, Amengual JE, Boonstra PS, Devata S, Wilcox RA, Kaminski MS, Phillips TJ (2019). Multicentre retrospective study of intravascular large B-cell lymphoma treated at academic institutions within the United States. Br J Haematol, 186(2), 255-262.
  43. Awan FT, Schuh A, Brown JR, Furman RR, Pagel JM, Hillmen P, Stephens DM, Woyach J, Bibikova E, Charuworn P, Frigault MM, Hamdy A, Izumi R, Linghu B, Patel P, Wang MH, Byrd JC (2018). Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib. Blood Adv, 3(9), 1553-1562.
  44. Stephens DM, Byrd JC (2019). How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia. Blood, 133(12), 1298-1307.
  45. Stephens DM (2019). Highs and lows of minimal residual disease in CLL. Blood, 133(5), 386-388.
  46. Havard R, Stephens DM (2018). Anti-CD19 Chimeric Antigen Receptor T Cell Therapies: Harnessing the Power of the Immune System to Fight Diffuse Large B Cell Lymphoma. Curr Hematol Malig Rep, 13(6), 534-542.
  47. Rogers KA, Huang Y, Ruppert AS, Salem G, Stephens DM, Heerema NA, Andritsos LA, Awan FT, Byrd JC, Flynn JM, Maddocks KJ, Jones JA (2018). A single-institution retrospective cohort study of first-line R-EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor. Br J Haematol, 180(2), 259-266.
  48. Wierda WG, Byrd JC, Abramson JS, Bhat S, Bociek G, Brander D, Brown J, Chanan-Khan A, Coutre SE, Davis RS, Fletcher CD, Hill B, Kahl BS, Kamdar M, Kaplan LD, Khan N, Kipps TJ, Lancet J, Ma S, Malek S, Mosse C, Shadman M, Siddiqi T, Stephens D, Wagner N, Zelenetz AD, Dwyer MA, Sundar H (2017). Hairy Cell Leukemia, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 15, 1414-1427.
  49. Giulino-Roth L, ODonohue T, Chen Z, Bartlett NL, LaCasce A, Martin-Doyle W, Barth MJ, Davies K, Blum KA, Christian B, Casulo C, Smith SM, Godfrey J, Termuhlen A, Oberley MJ, Alexander S, Weitzman S, Appel B, Mizukawa B, Svoboda J, Afify Z, Pauly M, Dave H, Gardner R, Stephens DM, Zeitler WA, Forlenza C, Levine J, Williams ME, Sima JL, Bollard CM, Leonard JP (2017). Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R. Br J Haematol, 179(5), 739-747.
  50. Stephens DM (2017). Brentuximab: is it time for a new "B" in ABVD? Blood, 130(11), 1281-1282.
  51. Haverkos BM, Abbott D, Hamadani M, Armand P, Flowers ME, Merryman R, Kamdar M, Kanate AS, Saad A, Mehta A, Ganguly S, Fenske TS, Hari P, Lowsky R, Andritsos L, Jagasia M, Bashey A, Brown S, Bachanova V, Stephens D, Mineishi S, Nakamura R, Chen YB, Blazar BR, Gutman J, Devine SM (2017). PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD. Blood, 130(2), 221-228.
  52. Awan FT, Schuh A, Brown JR, Furman RR, Pagel JM, Hillmen P, Stephens DM, Woyach J, Bibikova E, Charuworn P, Frigault MM, Hamdy A, Izumi R, Linghu B, Patel P, Wang MH, Byrd JC (2016). Acalabrutinib monotherapy in patients with ibrutinib intolerance: results from the phase 1/2 ACE-CL-001 clinical study. Blood, 128(22), 638.
  53. Vrontikis A, Carey J, Gilreath JA, Halwani A, Stephens DM, Sweetenham JW (2016). Proposed Algorithm for Managing Ibrutinib-Related Atrial Fibrillation. Oncology (Williston Park), 30(11), 970-4, 980-1, C3.
  54. Haverkos BM, Schowinksy J, Kaplan J, Kamdar M, Kanate AS, Saad A, Mehta A, Ganguly S, Flowers MED, Fensky TS, Hari P, Hamadani M, Lowsky R, Andritsos L, Jagasia MH, Brown S, Armand P, Merryman RW, Bachanova V, Stephens DM, Nakamura R, Gutman JA, Devine SM (2016). Checkpoint Blockade for Treatment of Relapsed Lymphoma Following Allogeneic Hematopoietic Cell Transplant: Use May be Complicated By Onset of Severe Acute Graft Versus Host Disease. Blood, 128(22), 1163.
  55. Stephens DM, Li H, LeBlanc ML, Puvvada SD, Persky D, Friedberg JW, Smith SM (2016). Continued Risk of Relapse Independent of Treatment Modality in Limited-Stage Diffuse Large B-Cell Lymphoma: Final and Long-Term Analysis of Southwest Oncology Group Study S8736. J Clin Oncol, 34(25), 2997-3004.
  56. Stephens DM, Goodrich AL (2016). Risk-Stratified Treatment in Chronic Lymphocytic Leukemia. J Adv Pract Oncol, 7(3), 314-317.
  57. Luo C, Deng Z, Li L, Clayton F, Chen AL, Wei R, Miles R, Stephens DM, Glenn M, Wang X, Jensen PE, Chen X (2016). Association of rituximab with graphene oxide confers direct cytotoxicity for CD20-positive lymphoma cells. Oncotarget, 7(11), 12806-22.
  58. Byrd JC, Harrington B, OBrien S, Jones JA, Schuh A, Devereux S, Chaves J, Wierda WG, Awan FT, Brown JR, Hillmen P, Stephens DM, Ghia P, Barrientos JC, Pagel JM, Woyach J, Johnson D, Huang J, Wang X, Kaptein A, Lannutti BJ, Covey T, Fardis M, McGreivy J, Hamdy A, Rothbaum W, Izumi R, Diacovo TG, Johnson AJ, Furman RR (2016). Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med, 374(4), 323-32.
  59. Stephens DM, Ruppert AS, Weirda WG, Jones JA, Woyach JA, Maddocks K, Jaglowski SM, Andritsos LA, Flynn JM, Grever MR, Lozanski G, Tam C, OBrien S, Keating MJ, Muthusamy N, Abruzzo LV, Heerema NA, Byrd JC (2015). Externally validated predictive clinical model for untreated del(17p13.1) chronic lymphocytic leukemia patients. Am J Hematol, 90(11), 967-9.
  60. Stephens DM, Spurgeon SE (2015). Ibrutinib in mantle cell lymphoma patients: glass half full? Evidence and opinion. Ther Adv Hematol, 6(5), 242-52.
  61. Miller CR, Stephens D, Ruppert AS, Racke F, McFaddin A, Breidenbach H, Lin HJ, Waller K, Bannerman T, Jones JA, Woyach JA, Andritsos LA, Maddocks K, Zhao W, Lozanski G, Flynn JM, Grever M, Byrd JC, Heerema NA (2015). Jumping translocations, a novel finding in chronic lymphocytic leukaemia. Br J Haematol, 170(2), 200-7.
  62. Rogers KA, Salem G, Stephens DM, Andritsos LA, Awan FT, Byrd JC, Flynn JM, Maddocks KJ, Huang Y, Ruppert AS, Jones JA (2015). A single-institution retrospective cohort study of patients treated with R-EPOCH for Richter’s transformation of chronic lymphocytic leukemia. Blood, 126(23), 2951.
  63. Stephens DM, Ruppert AS, Jones JA, Woyach J, Maddocks K, Jaglowski SM, Andritsos LA, Flynn JM, Grever MR, Lozanski G, Johnson AJ, Muthusamy N, Heerema NA, Byrd JC (2014). Impact of targeted therapy on outcome of chronic lymphocytic leukemia patients with relapsed del(17p13.1) karyotype at a single center. Leukemia, 28(6), 1365-8.
  64. Cheney CM, Stephens DM, Mo X, Rafiq S, Butchar J, Flynn JM, Jones JA, Maddocks K, OReilly A, Ramachandran A, Tridandapani S, Muthusamy N, Byrd JC (2014). Ocaratuzumab, an Fc-engineered antibody demonstrates enhanced antibody-dependent cell-mediated cytotoxicity in chronic lymphocytic leukemia. MAbs, 6(3), 749-55.
  65. Stephens DM, Ruppert AS, Maddocks K, Andritsos L, Baiocchi R, Jones J, Johnson AJ, Smith LL, Zhao Y, Ling Y, Li J, Phelps MA, Grever MR, Byrd JC, Flynn JM (2013). Cyclophosphamide, alvocidib (flavopiridol), and rituximab, a novel feasible chemoimmunotherapy regimen for patients with high-risk chronic lymphocytic leukemia. Leuk Res, 37(10), 1195-9.
  66. Stephens DM, Stark A, Jones JA, Woyach JA, Maddocks K, Jaglowski SM, Andritsos LA, Flynn JM, Grever MR, Lozanski G, Johnson AJ, Muthusamy N, Heerema NA, Byrd JC (2013). Changing the treatment paradigm for previously treated chronic lymphocytic leukemia patients with del(17p) karyotype. Blood, 122(21), 2872.
  67. Stephens DM, Byrd JC (2013). Chronic lymphocytic leukemia with del(17p13.1): a distinct clinical subtype requiring novel treatment approaches. Oncology (Williston Park), 26(11), 1044-54.
  68. Stephens DM, Ruppert AS, Blum K, Jones J, Flynn JM, Johnson AJ, Ji J, Phelps MA, Grever MR, Byrd JC (2012). Flavopiridol treatment of patients aged 70 or older with refractory or relapsed chronic lymphocytic leukemia is a feasible and active therapeutic approach. Haematologica, 97(3), 423-7.
  69. Stephens DM, Ruppert AS, Blum K, Jones J, Flynn JM, Johnson AJ, Ji J, Phelps MA, Grever MR, and Byrd JC (03/01/2012). Flavopiridol treatment of patients aged 70 or older with refractory or relapsed chronic lymphocytic leukemia is a feasible and active therapeutic approach. Haematologica, 97(3), 423-427.
  70. Mickelson DM, Sproat L, Dean R, Sobecks R, Rybicki L, Kalaycio M, Pohlman B, Sweetenham J, Andresen S, Bolwell B, Copelan EA (2011). Comparison of donor chimerism following myeloablative and nonmyeloablative allogeneic hematopoietic SCT. Bone Marrow Transplant, 46(1), 84-9.
  71. Mickelson DM, Hatem S, and Copelan E (02/01/2010). Granulocyte Simulating-Colony Factor-Associated Splenic Artery Rupture. Leuk Lymphoma, 51(2), 335-337.

Review

  1. Stephens DMByrd JC (Submitted). Resistance to Bruton’s Tyrosine Kinase Inhibitors: The Achilles Heel of Their Success Story in Lymphoid Malignancies Next-Generation Bruton Tyrosine Kinase Inhibitors. Accepted for publication. [Review]. Blood.
  2. Shah H, Stephens DM, Seymour J, Maddocks K (Pending). Incorporating novel targeted and immunotherapeutic agents in treatment of B-cell lymphomas. 2021 Feb. Accepted for publication. [Review]. J Clin Oncol.
  3. Stephens DM, Byrd JC (2020). Next-Generation Bruton Tyrosine Kinase Inhibitors. [Review]. Am J Clin Oncol, JCO2001594.
  4. Shadman M, Stephens DM (2020). Debate: What is optimal first-line therapy for chronic lymphocytic leukemia? [Review]. J Natl Compr Canc Netw, 18(7.5), 993-997.
  5. Stephens DM (2019). Venetoclax and obinutuzumab for front-line treatment of chronic lymphocytic leukemia. [Review]. Blood, 134(20), 1691-1696.
  6. Stephens DM (2019). Highs and lows of minimal residual disease in CLL. [Review]. Blood, 133(5), 386-388.
  7. Stephens DM, Byrd JC (2019). How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia. . [Review]. Blood, 133(12), 1298-1307.
  8. Harvard R, Stephens DM (2018). Anti-CD19 Chimeric Antigen Receptor T Cell Therapies:  Harnessing the Power of the Immune System to Fight Diffuse Large B Cell Lymphoma. [Review]. Curr Hematol Malig Rep, 13(6), 534-542.
  9. Stephens DM, Smith SM (2018). Diffuse large B-cell lymphoma-Who should we FISH? [Review]. 2, 2616-2695.
  10. Voorhies BN, Stephens DM (2017). What Is Optimal Front-Line Therapy for Chronic Lymphocytic Leukemia in 2017? [Review]. Curr Treat Options Oncol, 18(2), 12.
  11. Stephens DM, Goodrich AL (2016). Risk-Stratified Treatment in Chronic Lymphocytic Leukemia. [Review]. J Adv Pract Oncol, 7(3), 314-317.
  12. Stephens DM, Sweetenham JW (04/11/2015). Clinical controversies of double-hit lymphoma. [Review]. Am J Hematol Oncol, 11(4), 10-16.
  13. Stephens DM, Byrd JC (2013). Improving the treatment outcome of patients with chronic lymphocytic leukemia through targeted antibody therapy. [Review]. Hematol Oncol Clin North Am, 27(2), 303-27.
  14. Stephens DM, Byrd JC (11/1/2012). Chronic lymphocytic leukemia with del(17p13.1): A distinct clinical subtype requiring novel treatment approaches. [Review]. Oncology, 11, 1044-1054.
  15. Stephens DM, Byrd JC (2012). Ask the hematologists: Is there a standard of care for treating older patients with chronic lymphocytic leukemia? [Review]. 9(4), 4.
  16. Stephens DM, Byrd JC (2012). Chronic lymphocytic leukemia with del(17p13.1): a distinct clinical subtype requiring novel treatment approaches. [Review]. Oncology, 26(11), 1044-1054.
  17. Mickelson DM, Mady E, and Teng K (2009). A 43 year-old woman with chest pressure: a review of hypercoagulable states. [Review]. Cleve Clin J Med, 76(3), 191-8.

Conference Proceedings

  1. Gordon M, Kaempf A, Sitlinger A, Salous T, Alqahtani H, Churnetski MC, Wisniewski P, Rivera X, Patel K, Persky D, Cohen JB, Choi M, Hill BT, Shadman M, Stephens DM, Brander D, Park B, Danilov AV (2020). The chronic lymphocytic leukemia comorbidity index (CLL-CI) predicts survival and tolerance of ibrutinib therapy in patients with CLL: A multicenter retrospective cohort study.  . American Society of Hematology Meeting, San Diego, California.
  2. Orellana-Noia V, Reed D, Sen J, Barlow C, Malecek M, Watkins M, Kahl B, Spinner M, Advani R, Voorhees T, Snow A, Grover N, Ayers A, Romacik J, Liu Y, Huntington S, Chavez J, Saeed H, Lazaryan A, Raghunathan V, Spurgeon S, Ollila T, Del Potro C, Olszewski A, Ayers E, Landsburg D, Echaier B, Lee J, Kamdar M, Caimi P, Fu T, Liu J, David K, Alharthy H, Law J, Karmali R, Shah H, Stephens DM, Major A, Rojek A, Smith S, Yellala A, Kallam A, Nakhoda S, Khan N, Cohen J, Portel C (2020). Prophylaxis during front-Line therapy in aggressive non-Hodgkin lymphomas: Real-world outcomes and practice patterns from 19 US academic institutions.  . American Society of Hematology Meeting, San Diego, California.
  3. Siddiqi T, Soumerai JD, Dorritie KA, Stephens DM, Riedell PA, Arnason J, Kipps TJ, Gillenwater HH, Gong L, Yang L, Ogasawara K, Wierda WG (2020). Updated follow-up of patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma treated with lisocabtagene maraleucel in the phase 1 monotherapy cohort of TRANSCEND CLL 004, including high-risk and ibrutinib-treated patients. American Society of Hematology Meeting, San Diego, California.
  4. Wierda WG, Dorritie KA, Munoz J, Stephens DM, Solomon S, Gillenwater HH, Gong L, Yang L, Ogasawara K, Thorpe J, Siddiqi T (2020). TRANSCEND CLL 004: Phase 1 cohort of lisocabtagene maraleucel (liso-cel) in combination with ibrutinib for patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). American Society of Hematology Meeting, San Diego, California.
  5. Brown JR, Byrd JC, Ghia P, Sharman JP, Hillmen P, Stephens DM, Sun C, Jurczak W, Pagel JM, Ferrajoli A, Patel P, Baek M, Lezhava T, Kuptsova-Clarkson N, Moslehi J, Furman RR (2020). Pooled analysis of cardiovascular events from clinical trials evaluating acalabrutinib monotherapy in patients with chronic lymphocytic leukemia. American Society of Hematology Meeting, San Diego, California.
  6. Karmali R, Abramson JS, Stephens DM, Barnes J, Kaplan J, Winter JN, Ma S, Gao J, Petrich A, Hochberg E, Takvorian T, Kuhr F, Nelson V, Gordon LI, Pro, B (2020). Ibrutinib maintenance (I-M) following frontline intensive induction in mantle cell lymphoma (MCL): assessment of efficacy, safety and changes in minimal residual disease. American Society of Hematology Meeting, San Diego, California.
  7. Blachly JS, Lamanna N, Stephens DM, Ye CJ, Niesman M, Zhang K, Woyach JA (2020). Initial results from a phase 1 dose escalation study evaluating MS-553, a novel, selective PKC-beta inhibitor, in relapsed or refractory CLL/SLL patients. American Society of Hematology Meeting, San Diego, California.
  8. Wierda WGDorritieKA, Munoz J, Stephens DM, Solomon S, Gillenwater HH, Gong L, Yang L, Ogasawara K, Thorpe J, Siddiqi T (2020). TRANSCEND CLL 004: Phase 1 cohort of lisocabtagene maraleucel (liso-cel), a CD19-directed CAR T cell product, in combination with ibrutinib for patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).    . American Society of Clinical Oncology Meeting, Chicago, Illinois.
  9. Rogers KA, Wei L, Bhatt S, Jones D, Seymour E, Stephens DM, Ye C, Byrd JC, Woyach JA (2019). A multicenter study of ibrutinib resistance development and intervention with venetoclax. American Society of Hematology Meeting, Orlando, Florida.
  10. Hamid MS, Rutherford SC, Kim S, Bartlett N, Kate-Malecek M, Watkins M, Maddocks K, Bond D, Feldman T, Magarelli G, Advani R, Spinner M, Ahmed S, Stephens DM, Allen P, Patel K, Tees MT, Karmali R, Cheson B, Yazdy MS, Link B, Strouse C, Pagel JM, Ramchandren R (2019). Risk adapted approach for PET-2 positive Hodgkin lymphoma in the real world setting.  . American Society of Hematology Meeting, Orlando, Florida.
  11. Karmali R, Abramson J, Stephens DM, Barnes J, Kaplan J, Winter J, Ma S, Gao J, Petrich A, Hochberg E, Takvorian T, Kuhr F, Nelson V, Gordon LI, Pro B (2019). Interim safety, response and MRD evaluation in mantle cell lymphoma (MCL) patients treated with frontline intensive induction chemotherapy followed by ibrutinib maintenance. . American Society of Hematology Meeting, Orlando, Florida.
  12. Byrd JC, Wierda W, Schuh, Devereux S, Chaves JM, Brown JR, Hillmen P, Martin P, Awan FT, Stephens DM, Ghia P, Barrientos J, Pagel JM, Woyach JA, Burke K, Covey T, Gulrajani M, Hamdy A, Izumi R, Frigault MM, Patel P, Rothbaum W, Wang MH, OBrien S, Furman RR (2019). Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: 45-Month follow-up of a phase 2 study. . American Society of Hematology Meeting, Orlando, Florida.
  13. Siddiqi T, Soumerai JD, Dorritie KA, Stephens DM, Riedell PA, Arnason J, Kipps TJ, Gillenwater HH, Gong L, Dubovsky JA, Rytlewski J, Yang L, Wierda WG (2019). Rapid undetectable MRD responses in patients with relapsed/refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma treated with lisocabtagene maraleucel (liso-cel), a CD19-directed CAR T Cell product: Updated results from TRANSCEND CLL 004, a phase 1/2 study including patients with high-risk disease previously treated with ibrutinib.    . American Society of Hematology Meeting, Orlando, Florida.
  14. Kittai A, Gordon M, Mian A, Fitzgerald L, Bishop J, Stephens DM, Nagle S, Hill B, Danilov A (2019). Comorbidities predict inferior survival in patients receiving CAR T-cell therapy for relapsed/refractory DLBCL: A multicenter retrospective analysis.    . American Society of Hematology Meeting, Orlando, Florida.
  15. Woyach JA, Stephens DM, Flinn I, Bhat S, Savage R, Chai F, Eathiraj S, Granlund L, Szuszkiewicz L, Schwartz B, Byrd JC (2019). Final results of a phase 1, dose escalation study evaluating ARQ 531 in patients with relapsed or refractory B-Cell lymphoid malignancies. American Society of Hematology Meeting, Orlando, Florida.
  16. Persky DO, Li H, Stephens DM, Park SI, Bartlett N, Swinnen LJ, Barr PM, Winegarden JD, Constine LS, Fitzgerald TJ, Leonard JP, Kahl BS, LeBlanc ML, Song JY, Fisher RI, Rimsza LM, Smith SM, Friedberg JW (2019). PET-Directed therapy for patients with limited-stage diffuse large B-Cell lymphoma - Results of Intergroup NCTN Study S1001. . American Society of Hematology Meeting, Orlando, Florida.
  17. Stephens, DM, Huang Y, Ruppert AS, Agyeman A, Hu B, Turner N, Vadeboncoeur R, Rogers K, Bhat S, Basem W, Jaglowski SM, Hockman H, Glenn MJ, Lapalombella R, Byrd JC, Woyach J (2019). Selinexor combined with ibrutinib demonstrates tolerability and efficacy in advanced B-cell malignancies: A phase I study. . American Society of Hematology Meeting, Orlando, Florida.
  18. Siddiqi T, Dorritie KA, Soumerai JD, Stephens DM, Dubovsky JA, Gillenwater HH, Gong L, Thorpe J, Yang L, Wierda WG (2019). TRANSCEND 004 CLL: Minimal residual disease negative responses after lisocabtagene maraleucel (Liso-Cel; JCAR017), a CD19-directed CAR T cell product, in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.  . American Society of Clinical Oncology Meeting, Chicago, Illinois.
  19. Karmali R, Abramson JS, Stephens DM, Barnes JA, Kaplan JB, Winter JN, Ma S, Petrich AM, Hochberg EP, Takvorian T, Nelson V, Gordon LI, Pro B (2019). Ibrutinib maintenance following induction for untreated mantle cell lymphoma: Initial safety report.  . American Society of Clinical Oncology Meeting, Chicago, Illinois.
  20. Byrd J, Woyach J, Furman R, Martin P, OBrien S, Brown J, Stephens D, Barrientos J, Devereux S, Hillmen P, Pagel J, Hamdy A, Izumi R, Patel P, Wang MH, Jain N, Wierda W (2019). Acalabrutinib in treatment-naïve chronic lymphocytic leukemia: Mature results from phase 2 study demonstrating durable remission and long-term tolerability.    . European Hematology Association Meeting, Frankfurt, Germany.
  21. Byrd JC, Woyach JA, Furman RR, Martin P, OBrien SM, Brown JR, Stephens DM, Barrientos JC, Devereux S, Hillemen P, Pagel JM, Chen D, Hamdy A, Izumi R, Patel P, Wan MH, Jain N, Wierda WG (December 2018). Acalabutinib in treatment-naive chronic lymphocytic leukemia: Updated results from phase 1/2 ACE-CL-001 study. American Society of Hematology Meeting, San Diego, California.
  22. Koffman B, Dennison B, Kennard K, Furman R, Byrd J, Pagel J, Davids MS, Nabhan C, Kay N, Brander D, Siddiqi T, Hill B, Pinilla-Ibarz J, Cheson B, Rosen ST, Wierda WG, Stephens DM, Awan FT, Choi MY, Mato AR (2018 Jun). A US-Based survey: The experiences and perspectives of 1147 chronic lymphocytic leukemia patients. European Hematology Association Meeting, Stockholm, Sweden.
  23. Geer M, Shango M, Till B, Smith SD, Abbas H, Hill BT, Kaplan J, Barr PM, Caimi P, Stephens DM, Lin E, Herrera AF, Rosenbaum E, Amengual JE, Roberts E, Boonstra PS, Devata S, Wilcox RA, Kaminski MS, Phillips TJ (2017). Multicenter retrospective study of features and outcomes of patients with intravascular DLBCL treated at academic institutions within the United States. American Society of Hematology Meeting, Atlanta.
  24. Byrd JC, Wierda W, Schuh A, Devereux S, Chaves JM, Brown JR, Hillmen P, Martin P, Awan FT, Stephens DM, Ghia P, Barrientos J, Pagel JM, Woyach JA, Charuworn P, Hamdy A, Izumi R, Patel P, Wan MH, Furman RR (2017). Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: Updated results from the phase 1/2 ACE-CL-001 Study. American Society of Hematology Meeting, Atlanta, Georgia.
  25. Awan FT, Schuh A, Brown JR, Furman RR, Pagel JM, Hillmen P, Stephens DM, Hamdy A, Huang J, Izumi R, Patel P, Wang MH, Byrd JC (2016). Acalabrutinib monotherapy in patients with ibrutinib: results from the phase 1/2 ACE-CL-001 clinical study. American Society of Hematology Meeting, Sand Diego.
  26. Haverkos BM, Schowinksy J, Kaplan JB, Kamdar M, Kanate AS, Saad A, Ganguly S, Flowers M, Fenske TS, Hari P, Hamadani M, Lowsky R, Andritsos L, Jagasia M, Brown S, Armand P, Merryman R, Bachanova V, Stephens DM, Nakumura R, Gutman J, Devine SM (2016 Dec). Checkpoint blockade for treatment of lymphoma following allogeneic stem cell transplant: use may be complicated by onset of severe acute graft versus host disease. American Society of Hematology Meeting, San Diego.
  27. Awan FT, Schuh A, Brown JR, Furman RR, Pagel JM, Hillmen P, Stephens DM, Hamdy A, Huang J, Izumi R, Patel P, Wang MH, Byrd JC (2016 Dec). Acalabrutinib monotherapy in patients with ibrutinibi: results from the phase 1/2 ACE-CL-001 clinical study. American Society of Hematology Meeting, San Diego, California.
  28. Haverkos BM, Schowinksy J, Kaplan JB, Kamdar M, Kanate AS, Saad A, Ganguly S, Flowers M, Fenske TS, Hari P, Hamadani M, Lowsky R, Andritsos L, Jagasia M, Brown S, Armand P, Merryman R, Bachanova V, Stephens DM, Nakumura R, Gutman J, Devine SM (12/03/2016). Checkpoint blockade for treatment of lymphoma following allogeneic stem cell transplant: use may be complicated by onset of severe acute graft versus host disease. American Society of Hematology Meeting, San Diego.
  29. Stephens DM, Starodub AN, Byrd JC, Wegener, WA, Horne H, Goldenberg, DM, Christian BA (07/15/2016). Subcutaneous injections of IMMU-114 (anti-HLA-DR IgG4 monoclonal antibody): Initial results of a phase I first-in-man study in hematologic malignancies. Pan-Pacific Lymphoma Conference, Poipu, Hawaii.
  30. Byrd JC, Jones JA, Furman RR, Stephens DM, Devereux S, Brown JR, Hillmen P, Hamdy AM, Wang MH, Patel P, Mittag D, Krantz M, Rothbaum W, Izumi R, OBrien SM, Wierda WG (06/15/2016). Acalabrutinib, a second-generation Bruton tyrosine kinase inhibitor, in previously untreated chronic lymphocytic leukemia. American Society of Clinical Oncology Annual Meeting, Chicago.
  31. Wierda WG, Jones JA, Furman RR, Stephens DM, Devereux S, Brown JR, Hillmen P, Hamdy A, Fardis M, Tawashi M, Wang MH, Patel P, Mittag D, Krantz F, Rothbaum W, Izumi R, OBrien S, Byrd JC (2016 Jun). Acalabrutinib, a second-generation Bruton tyrosine kinase inhibitor, in previously untreated chronic lymphocytic leukemia. European Hematology Association Annual Meeting, Copenhagen, Denmark.
  32. Byrd JC, Wierda WG, Jones JA, OBrien S, Brown JR, Schuh A, Hillmen P, Stephens DM, Gia P, Devereux S, Chaves J, Barrientos JC, Wan MH, Huang J, Covey T, Navarro T, Hamdy A, Furman RR (2015 Dec). The Bruton tyrosine kinase (Btk) inhibitor ACP-196: Marked activity in relapsed/refractory CLL with a favorable safety profile. American Society of Hematology Meeting, Orlando, Florida.
  33. Stephens DM, Starodub AN, Byrd JC, Wegener, WA, Horne H, Goldenberg, DM, Christian BA (12/01/2015). Subcutaneous injections of IMMU-114 (anti-HLA-DR IgG4 monoclonal antibody): Initial results of a phase I first-in-man study in hematologic malignancies. Orlando, Florida: American Society of Hematology Meeting.
  34. Stephens DM, LeBlanc ML, Li H, Miller TP, Puvvada SD, Persky D, Friedberg J, Smith SM (06/19/2015). Continued risk of relapse independent of treatment modality in limted stage diffuse large B-cell lymphoma: Final and long-term analysis of SWOG study S8736. 13th International Conference on Malignant Lymphoma, Lugano, Switzerland.
  35. Stephens DM, Stark A, Jones JA, Woyach JA, Maddocks K, Jaglowski SM, Andritsos LA, Flynn JM, Grever MR, Lozanski G, Johnson AJ, Muthusamy N, Heerema NA, Byrd JC (2013). Changing the treatment paradigm for previously treated chronic lymphocytic leukemia patients with del(17p) karyotype. New Orleans, LA: American Society of Hematology Meeting.
  36. Stephens DM, Cheney CM, Mo X, Rafiq S, Butchar J, Flynn JM, Jones JA, Maddocks K, OReilly A, Ramachandran A, Tidandapani S, Muthusamy N, and Byrd JC (2013). Ocaratuzumab, a proposed effective and convenient alternative for treatment of chronic lymphocytic leukemia. Cologne, Germany: International Workshop on Chronic Lymphocytic Leukemia.
  37. Stephens DM, Ruppert AS, Woyach JA, Maddocks K, Jaglowski SM, Andritsos LA, Jones JA, Flynn JM, Grever MR, Hareema N, Muthusamy N, and Byrd JC (06/01/2013). Predictive clinical model for untreated del(17p13.1) chronic lymphocytic leukemia patients. Stockholm, Sweden: European Hematology Association International Congress.
  38. Stephens DM, Maddocks K, Andritsos L, Baiocchi R, Jones J, Phelps M, Johnson AJ, Smith L, Grever MR, Byrd JC, and Flynn JM (06/01/2012). Phase I feasibility trial of cyclophosphamide, alvocidib (flavopiridol) and rituximab in patients with high-risk b-cell chronic lymphocytic leukemia/small lymphocytic lymphoma. Amsterdam, Netherlands: European Hematology Association International Congress.
  39. Stephens DM, Ruppert AS, Blum K, Jones J, Flynn JM, Johnson AJ, Ji J, Phelps MA, Grever MR, and Byrd JC (12/01/2010). Flavopiridol treatment of patients aged 70 or older with refractory or relapsed chronic lymphocytic leukemia is a feasible and active therapeutic approach. Orlando, Florida: American Society of Hematology Meeting.
  40. Mickelson D, Sproat L, Dean R, Sobecks R, Rybicki L, Kalaycio M, Pohlman B, Sweetenham J, Andresen S, Bolwell B, and Copelan E (02/01/2009). T-cell engraftment kinetics following myeloablative and nonmyeloablative regimens for allogeneic hematopoietic stem-cell transplantation. Tampa, Florida: American Society for Blood and Marrow Transplantation.

Commentary

  1. Stephens DM (2017). Brentuximab: is it time for a new "B" in ABVD? Blood, 130(11), 1281-1282.
  2. Stephens DM (2016). Allogeneic Stem Cell Transplantation in Chronic Lymphocytic Leukemia: An Archaic Intervention or a Necessary Evil? Oncology (Williston Park), 30(6), 539-40.

Case Report

  1. Shah HR, Stephens DM (2021). Is there a role for anti-CD20 antibodies in CLL? Hematology Am Soc Hematol Educ Program, 2021(1), 68-75.
  2. Fitzgerald L, Stephens DM (2020). Burkitt Lymphoma Presenting as Cranial Multineuritis Secondary to Primary Neurolymphomatosis: A Diagnostic Challenge. Clin Lymphoma Myeloma Leuk, 20(4), e201-e204.
  3. Laggis C, Miles R, Stephens DM, Duffy K, Bowen A, Wada D (2019). Cutaneous mantle cell lymphoma histomorphologically mimicking subcutaneous panniculitis-like T-cell lymphoma: Case report. J Cutan Pathol, 46(7), 538-541.
  4. Fitzgerald LA, Stephens DM (22 June 2017). Seeing Double: A Rare Presentation of Non-Hodgkin Lymphoma. Ann Hematol Oncol, 4(6), 1155.
  5. Juster-Switlyk K, Smith AG, Kovacsovics T, Stephens D, Glenn M, Palmer CA, Quigley EP 3rd, Kolb N (2017). MTHFR C677T polymorphism is associated with methotrexate-induced myelopathy risk. Neurology, 88(6), 603-604.

Editorial

  1. Stephens DM (2021). Second-Generation Bruton's Tyrosine Kinase Inhibitors: Simply the Best Treatments for Chronic Lymphocytic Leukemia? J Clin Oncol, 39(31), 3419-3422.

Letter

  1. Vardell VA, Ermann DA, Fitzgerald LA, Shah HR, Hu B, Stephens DM (2023). Influence of racial and ethnic identity on overall survival in patients with chronic lymphocytic leukemia. [Letter to the editor]. Am J Hematol, 98(7), E172-E174.
  2. Stephens DM, Schoder H, Li H, Friedberg J (2020). Reply: Interim PET Assessment of Advanced Hodgkin Lymphoma: Is It Sufficient? [Letter to the editor]. J Nucl Med, 61(11), 1695.
  3. Koffman B, Mato A, Byrd JC, Danilov A, Hedrick B, Ujjani C, Roeker L, Stephens DM, Davids MS, Pagel JM, Shadman M (2020). Management of CLL patients early in the COVID-19 pandemic: An international survey of CLL experts. [Letter to the editor]. Am J Hematol, 95(8), E199-E203.

Abstract

  1. Giulino-Roth L, ODonohue T, Chen Z, Bartlett NL, LaCasce A, Martin-Doyle W, Barth MJ, Davies K, Blum KA, Christian B, Casulo C, Smith SM, Godfrey J, Termuhlen A, Oberlye MJ, Alexander S, Weitzman S, Appel B, Mizukawa B, Svoboda J, Afify Z, Pauly M, Dave H, Gardner R, Stephens DM, Zeitler WA, Forlenza C, Levine J, Williams ME, Sima JL, Bollard CM, Leonard JP (2017). Outcomes of adults, adolescents, and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R therapy: a multicenter retrospective analysis [Abstract]. Hematological Oncology, 35(S2), 61-2.
  2. Awan FT, Schuh A, Brown JR, Furman RR, Pagel JM, Hillmen P, Stephens DM, Hamdy A, Huang J, Izumi R, Patel P, Wang MH, Byrd JC (12/03/2016). Acalabrutinib monotherapy in patients with ibrutinibi: results from the phase 1/2 ACE-CL-001 clinical study [Abstract]. Blood, 128(22), 638.
  3. Stephens DM, Ruppert AS, Christian B, Jones J, Flynn JM, Porcu P, Baiocchi R, Byrd JC, Dotson EK, Crawford BS, and Blum KA (2012). Toxicity in patients 65 years with dose adjusted REPOCH for untreated diffuse large B cell lymphoma [Abstract]. Journal of Clinical Oncology, 30(suppl), 15.
  4. Stephens DM, Ruppert AS, Christian B, Jones J, Flynn JM, Porcu P, Baiocchi R, Byrd JC, Dotson EK, Crawford BS, Blum KA (2012). Toxicity in patients ≥ 65 years with dose adjusted REPOCH for untreated diffuse large B cell lymphoma [Abstract]. Journal of Clinical Oncology (Meeting Abstracts), 30(suppl), 15.

News & Podcasts

Huntsman Cancer Institute News